Long-term trend in pediatric antidepressant use, 1983-2007: A population-based study

Canadian Journal of Psychiatry

Volumn 59, Issue 2, 2014, Pages 89-97

  Meng, Xiangfei ^a   D'Arcy, Carl ^a   Tempier, Raymond ^b  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b Hopital Montfort Hospital   (Canada)

Author keywords

Adolescents; Antidepressants; Children; Prescriptions; Saskatchewan; Trends

Indexed keywords

ANTIDEPRESSANT AGENT; MONOAMINE OXIDASE INHIBITOR; PRESCRIPTION DRUG; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADOLESCENT; ADULT; ARTICLE; CANADA; CHILD; CHILD PSYCHIATRY; DRUG USE; FEMALE; GENERAL PRACTITIONER; HUMAN; INFANT; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NEWBORN; OUTPATIENT DEPARTMENT; POPULATION RESEARCH; PRESCHOOL CHILD; PRESCRIPTION; SCHOOL CHILD; SEX DIFFERENCE; TREND STUDY; YOUNG ADULT;

ADOLESCENT; AGE FACTORS; AMBULATORY CARE; ANTIDEPRESSIVE AGENTS; CHILD; CHILD, PRESCHOOL; DEPRESSIVE DISORDER; DRUG UTILIZATION; FAMILY PRACTICE; FEMALE; HUMANS; INFANT; MALE; PHYSICIAN'S PRACTICE PATTERNS; SASKATCHEWAN; SEROTONIN UPTAKE INHIBITORS; SEX FACTORS; YOUNG ADULT;

EID: 84893819087     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674371405900204     Document Type: Article

References (38)

1. Murray ML, de Vries CS, Wong IC. A drug utilisation study of antidepressants in children and adolescents using the general practice research database. Arch Dis Child. 2004;89(12):1098-1102.
2. Stahl SM. Selecting an antidepressant by using mechanism of action to enhance effcacy and avoid side effects. J Clin Psychiatry. 1998;59(Suppl 18):23-29.
3. Zito JM, Tobi H, de Jong-van den Berg LT, et al. Antidepressant prevalence for youths: a multi-national comparison. Pharmacoepidemiol Drug Saf. 2006;15(11):793-798.
4. Fegert JM, Kolch M, Zito JM, et al. Antidepressant use in children and adolescents in Germany. J Child Adolesc Psychopharmacol. 2006;16(1-2):197-206.
5. Middleton N, Gunnell D, Whitley E, et al. Secular trends in antidepressant prescribing in the UK, 1975-1998. J Public Health Med. 2001;23(4):262-267.
6. Hernandez JF, Mantel-Teeuwisse AK, van Thiel GJ, et al. A 10-year analysis of the effects of media coverage of regulatory warnings on antidepressant use in the Netherlands and UK. PLOS ONE. 2012;7(9):e45515.
7. Papakostas GI. The effcacy, tolerability, and safety of contemporary antidepressants. J Clin Psychiatry. 2010;71(Suppl E1):E03.
8. Volkers AC, Heerdink ER, van Dijk L. Antidepressant use and off-label prescribing in children and adolescents in Dutch general practice (2001-2005). Pharmacoepidemiol Drug Saf. 2007;16(9):1054-1062.
9. Leon AC. The revised black box warning for antidepressants sets a public health experiment in motion. J Clin Psychiatry. 2007;68(7):1139-1141.
10. Libby AM, Brent DA, Morrato EH, et al. Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs. Am J Psychiatry. 2007;164(6):884-891.
11. Breggin PR. Recent US, Canadian and British regulatory agency actions concerning antidepressant-induced harm to self and others: a review and analysis. Int J Risk Saf Med. 2004;16:247-259.
12. Wijlaars LP, Nazareth I, Petersen I. Trends in depression and antidepressant prescribing in children and adolescents: a cohort study in The Health Improvement Network (THIN). PLOS ONE. 2012;7(3):e33181.
13. Dean AJ, Hendy A, McGuire T. Antidepressants in children and adolescents-changes in utilisation after safety warnings. Pharmacoepidemiol Drug Saf. 2007;16(9):1048-1053.
14. Holstein SA, Knapp HR, Clamon GH, et al. Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies. Cancer Chemother Pharmacol. 2006;57(2):155-164.
15. Zito JM, Safer DJ, de Jong-van den Berg LT, et al. A three-country comparison of psychotropic medication prevalence in youth. Child Adolesc Psychiatry Ment Health. 2008;2(1):26.
16. Parens E, Johnston J. Understanding the agreements and controversies surrounding childhood psychopharmacology. Child Adolesc Psychiatry Ment Health. 2008;2(1):5.
17. Tsapakis EM, Soldani F, Tondo L, et al. Effcacy of antidepressants in juvenile depression: meta-analysis. Br J Psychiatry. 2008;193(1):10-17.
18. Wadman M. Experts call for active surveillance of drug safety. Nature. 2007;446(7134):358-359.
19. Marchidon G, O'Fee K. Health care in Saskatchewan: an analytical profle. Regina (SK): Canadian Plains Research Center and the Saskatchewan Institute of Public Policy; 2007.
20. Rawson NS, Downey W, Maxwell CJ, et al. 25 years of pharmacoepidemiologic innovation: the Saskatchewan health administrative databases. J Popul Ther Clin Pharmacol. 2011;18(2):e245-e249.
21. Lack CW, Green AL. Mood disorders in children and adolescents. J Pediatr Nurs. 2009;24(1):13-25.
22. Muris P. Treatment of childhood anxiety disorders: what is the place for antidepressants? Expert Opin Pharmacother. 2012;13(1):43-64.
23. Costello EJ, Mustillo S, Erkanli A, et al. Prevalence and development of psychiatric disorders in childhood and adolescence. Arch Gen Psychiatry. 2003;60(8):837-844.
24. Jane Costello E, Erkanli A, Angold A. Is there an epidemic of child or adolescent depression? J Child Psychol Psychiatry. 2006;47(12):1263-1271.
25. O'Neil KA, Conner BT, Kendall PC. Internalizing disorders and substance use disorders in youth: comorbidity, risk, temporal order, and implications for intervention. Clin Psychol Rev. 2011;31(1):104-112.
26. Merikangas KR, Nakamura EF, Kessler RC. Epidemiology of mental disorders in children and adolescents. Dialogues Clin Neurosci. 2009;11(1):7-20.
27. Rapee RM, Schniering CA, Hudson JL. Anxiety disorders during childhood and adolescence: origins and treatment. Annu Rev Clin Psychol. 2009;5:311-341.
28. Cincinnati Children's Hospital Medical Center. Treatment of children and adolescents with major depressive disorder (MDD) during the acute phase. Cincinnati (OH): Cincinnati Children's Hospital Medical Center; 2010.
29. Tournier M, Greenfeld B, Galbaud du Fort G, et al. Patterns of antidepressant use in Quebec children and adolescents: trends and predictors. Psychiatry Res. 2010;179(1):57-63.
30. Chien IC, Hsu YC, Tan HK, et al. Trends, correlates, and disease patterns of antidepressant use among children and adolescents in Taiwan. J Child Neurol. 2013;28(6):706-712.
31. Vitiello B, Zuvekas SH, Norquist GS. National estimates of antidepressant medication use among US children, 1997-2002. J Am Acad Child Adolesc Psychiatry. 2006;45(3):271-279.
32. Katz LY, Kozyrskyj AL, Prior HJ, et al. Effect of regulatory warnings on antidepressant prescription rates, use of health services and outcomes among children, adolescents and young adults. CMAJ. 2008;178(8):1005-1011.
33. Murray ML, Thompson M, Santosh PJ, et al. Effects of the Committee on Safety of Medicines advice on antidepressant prescribing to children and adolescents in the UK. Drug Saf. 2005;28(12):1151-1157.
34. Rihmer Z, Akiskal H. Do antidepressants t(h)reat(en) depressives? Toward a clinically judicious formulation of the antidepressant-suicidality FDA advisory in light of declining national suicide statistics from many countries. J Affect Disord. 2006;94(1-3):3-13.
35. Zoega H, Baldursson G, Hrafnkelsson B, et al. Psychotropic drug use among Icelandic children: a nationwide population-based study. J Child Adolesc Psychopharmacol. 2009;19(6):757-764.
36. Delate T, Gelenberg AJ, Simmons VA, et al. Trends in the use of antidepressants in a national sample of commercially insured pediatric patients, 1998 to 2002. Psychiatr Serv. 2004;55(4):387-391.
37. Nemeroff CB, Kalali A, Keller MB, et al. Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States. Arch Gen Psychiatry. 2007;64(4):466-472.
38. Comer JS, Olfson M, Mojtabai R. National trends in child and adolescent psychotropic polypharmacy in offce-based practice, 1996-2007. J Am Acad Child Adolesc Psychiatry. 2010;49(10):1001-1010.